

The Lens on LEN: The basics on injectable lenacapavir as PrEP

In June and September of 2024, Gilead Sciences announced findings from two trials from the PURPOSE program testing injectable lenacapavir (LEN) for prevention of HIV.

In late June 2024, Gilead Sciences announced an early review of the data of the PURPOSE 1 trial by an independent monitoring board who found that LEN as PrEP was safe and highly effective against HIV, with 100% efficacy in the LEN arm of the study among 5,300 HIV-negative cisgender women ages 16-25 in Uganda and South Africa. No infections were seen among those receiving LEN.

In September 2024, Gilead announced that the PURPOSE 2 trial's independent monitoring board also found compelling evidence of benefit. In this trial, LEN reduced HIV incidence by 96% compared to a background incidence of HIV among 3,200 cisgender men and trans and non-binary people ages 16 or older in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States. There were two incident cases among those receiving LEN.


This advocates' primer provides background on the product and trials; a summary of the early findings of PURPOSE 1 & 2; key questions and next steps.

1. [What is LEN?](#)
2. [How is it different from CAB?](#)
3. [What trials are being done?](#)
4. [How was civil society engaged in the process?](#)
5. [What happens next?](#)
6. [What can advocates do now?](#)

What is LEN?

Lenacapavir (LEN) is an investigational antiretroviral drug that is being studied as a potential PrEP product. Injectable LEN is an HIV capsid inhibitor. Capsid inhibitors damage the protein shell that protects HIV's genetic material and enzymes needed for replication. Capsid inhibitors can degrade the HIV capsid during multiple stages of the viral life cycle. This prevents HIV from multiplying and can reduce the amount of HIV in the body.

Lenacapavir Foundation of our long-acting portfolio



LEN for PrEP is delivered in two subcutaneous injections in the abdomen once every six months. There is also an oral loading dose—two at the time of first injection and two more a day later. It was developed by Gilead Sciences, which is currently the sole manufacturer.

Lenacapavir has been approved for HIV treatment since 2022. Gilead developed lenacapavir for use against multi-drug resistant HIV. Lenacapavir for treatment is used in combination with other antiretrovirals and is administered every six months.


How is LEN different from CAB?

	Cabotegravir (CAB)	Lenacapavir (LEN)
ARV drug class	Integrase Strand Transfer Inhibitor	Capsid Inhibitor
Injection type	Intramuscular	Subcutaneous
Injection site	Gluteal muscle (buttocks)	Abdomen
Injection volume	One 3 ml injections	Two 1.5 ml injections
Frequency/interval	First injection followed by a second one month later, then every 2 months	First injection along with two oral tablets, followed by two more tablets on day 2 and then injections every 6 months
Efficacy	Very high efficacy in all populations	Very high efficacy among cisgender women; data in other populations pending
Regulatory approvals and guidelines	19 regulatory approvals as of June 2024; WHO recommendation as additional prevention option in July 2022	Regulatory submissions and potential normative guidance anticipated in 2025
Price in LMICs	±\$180/year	TBD
Developer/Manufacturer	ViiV Healthcare	Gilead Sciences
Generic Manufacturers	Three licenses through MPP to Aurobindo, Cipla and Viatrix – all Indian-based manufacturers, with expected earliest market access in 2027	Gilead announced its intention to sign direct voluntary licenses with generic drug makers in several regions

What trials are being done?

Overview of Lenacapavir (LEN) for PrEP Trials

- ★ Initial data
- ★ Possible data
- ✓ Possible earliest regulatory submissions
- ✓ Possible earliest regulatory approval and market entry with product from Gilead
- ◆ Possible earliest generic manufacturer(s)



The PURPOSE efficacy trials are testing LEN in various populations. Efficacy trials must be able to prove that new tools work and meet ethical standards by providing participants with the best available prevention package, requiring innovative trial designs as the prevention landscape improves. In PURPOSE 1 and PURPOSE 2, LEN was compared for efficacy to oral F/TDF as well as an estimated background incidence rate of HIV. Background incidence is an estimate of a baseline incident rate in the population being studied. It is one of several “external controls” the US FDA has begun to consider in these innovative designs to estimate what HIV incidence (the rate of new infections) might have been if the trial had included a placebo arm.

PURPOSE 1 enrolled more than 5,300 cisgender adolescent girls and young women ages 16-25 to evaluate injectable lenacapavir for PrEP and a daily pill of emtricitabine/tenofovir alafenamide (F/TAF, brand name DESCOPY) for PrEP. The studies were conducted across 25 sites in South Africa and three in Uganda. In June 2024, Gilead reported early results of efficacy in the lenacapavir arm, with zero infections compared to background incidence (bHIV) and compared to daily pills of F/TDF (brand name, Truvada). In PURPOSE 1, bHIV was 2.4%.

Based on the data reviewed in June 2024, the independent monitoring board recommended an early stop to the blinded phase of the trial and recommended the trial offer open-label LEN to all participants. If approved by regulators, LEN will be the second long-acting injectable PrEP option to enter the market.

An additional arm of the study tested daily oral F/TAF among the same population, compared to daily oral F/TDF and background incidence. Results show that F/TAF was numerically similar in its levels of protection to F/TDF, and was not protective overall when compared to background incidence due to overall low adherence. However, testing and data analysis show that F/TAF was protective against HIV in women with high adherence.

PURPOSE 1 also includes pregnant and lactating people, and the trial is conducting lenacapavir-exposure assessments during pregnancy, postpartum, in infants, and in breastmilk to support the potential use of this investigational product among pregnant and lactating people. There were 193 pregnancies among women in the lenacapavir group, with zero HIV infections; 219 among women in the F/TAF group, with four HIV infections; and 98 among women in the F/TDF group, with one HIV infection. Available pregnancy outcomes were similar to those expected for the population.

PURPOSE 2 enrolled 3,200 cisgender men, trans and non-binary people aged 16 years or older who have sex with men. The trial is evaluating the safety and efficacy of twice-yearly subcutaneous LEN for PrEP versus once-daily oral F/TDF and background HIV incidence (bHIV). The study was conducted across 88 sites in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the United States.

In September 2024, Gilead announced that lenacapavir reduced HIV acquisition by 96% compared to background HIV incidence, with 2 incident cases among 2,180 participants receiving LEN.

Based on the data, the independent monitoring board recommended an early stop to the blinded phase of this trial as well and recommended the trial offer open-label lenacapavir to all participants.

The trial set global goals for the inclusion of historically excluded and disproportionately affected populations. These include: 50% Black and 20% Hispanic/LatinX cisgender men who have sex with men among US-based enrollees; 20% transgender women globally. Transgender men and gender nonbinary individuals were intentionally enrolled for the first time in any Phase 3 PrEP trial.

Both **PURPOSE 1 and 2** include adolescents (16-17 years old) for the first time in PrEP efficacy trials. Safety and efficacy findings of LEN for this specific group are expected in the full data analysis.

PURPOSE 3 is a Phase 2, randomized, open-label study of safety and acceptability of injectable LEN for PrEP compared to oral TDF/FTC (brand name, Truvada) among cisgender women in the US who are disproportionately affected by HIV, with a focus on Black women and other women of color.

PURPOSE 4 is a Phase 2, randomized, open-label study to evaluate the safety and acceptability of injectable LEN for PrEP in people who inject drugs in the US.

PURPOSE 5 will be a Phase 2 study conducted in France and United Kingdom assessing consistent and continuous use of injectable LEN for PrEP compared with F/TDF in people who may benefit from PrEP but who are not currently taking it.

It will be imperative to understand how the early efficacy results of PURPOSE 1 and PURPOSE 2 will influence PURPOSE 3-5. Understanding the data and taking action to accelerate the introduction of proven products and expanding access to those products is key to ending the epidemic.

How was civil society engaged in the process?

The PURPOSE program represents an important advance in Gilead's research and development by incorporating civil society engagement and [Good Participatory Practice](#) (GPP). Across the PURPOSE program, GPP is helping to advance ethical and effective conduct of clinical trials, through consultations on study design and the establishment of Global Community Accountability Groups (GCAGs) for each PURPOSE efficacy study. These GCAGs grew out of multiple consultations during the protocol review process, including those led by AVAC and various partners.

Comprised of diverse stakeholders from historically underrepresented and disproportionately affected populations, GCAG members provide ongoing guidance, oversight and recommendations resulting in critical supports and more inclusive data-gathering, with broad implications for future access. These processes resulted in:

- The inclusion of adolescents.
- Participants offered free contraceptives without requiring their use.
- Allowing pregnant or breastfeeding participants to continue with the study.
- Monitoring for intimate partner violence and providing appropriate support.

These robust GPP practices are ensuring transparency and trust with trial communities and laying a foundation for product acceptability and use in the future.

What happens next?


There is no time to waste if the world is to translate these exciting clinical trial results into actual public health impact and expand the toolbox of HIV prevention choices. Lessons learned from rollout of daily oral PrEP, and more recently the dapivirine vaginal ring and injectable cabotegravir, can help speed regulatory approval, guideline development in key countries, the design of effective programs, and community understanding and acceptance of lenacapavir for PrEP. There are a number of concurrent actions that are needed now. Gilead, policy makers, normative agencies, donors, program implementers, researchers, generic manufacturers, civil society, advocates and communities each have critical roles to play in the coming months and years. AVAC is working with a wide range of partners to develop a comprehensive map of all the moving parts and identify specific priority actions and actors responsible for ensuring time is not wasted and opportunity not squandered. Essential priorities include:

- Gilead announced an early stop to the blinded phase of PURPOSE 1 and PURPOSE 2, with a transition to an open-label phase. [Gilead's statements on their planning](#) for access have committed to offering lenacapavir to all trial participants until the product is available through public health programs.
- Gilead now must expedite plans for submission to regulatory agencies, including the US Food and Drug Administration (FDA) and a robust number of additional regulatory agencies, especially in countries with high HIV burden. Regulatory agencies should prepare to fast-track regulatory review.
- WHO should initiate the process for developing guidelines, plan for a Guideline Development Group by early 2025, and ensure WHO Guidelines are in place by the time regulatory approvals might be granted, as early as mid-2025.
- PEPFAR and the Global Fund should work urgently with other donors and Ministries of Health to negotiate price and volume guarantees with Gilead to ensure there is a sustainable supply for the initial introduction period until generics are registered and readily available, likely at least three years.
- Funders, Ministries of Health, implementers and civil society partners need to collaboratively design a comprehensive introduction strategy that breaks the sequential nature of traditional approaches to scale and speed up introduction, moving toward a parallel approach where research, implementation science, and scaled programs are designed, funded and implemented in parallel. All stakeholders, with the support of the [Coalition to Accelerate Access to Long-Acting PrEP](#),

should commit to developing a robust introduction strategy ahead of regulatory approvals and WHO guidelines to ensure time is not lost, ideally with introduction happening by the end of 2025 in multiple geographies and populations.

- Following Gilead’s announcement that they are developing a direct voluntary licensing program for lenacapavir, it is imperative that Gilead grant non-exclusive licenses to multiple generic manufacturers in multiple geographies before the end of 2024 and even before regulatory submissions are made; that license agreements are made publicly available; that the licenses include access to finished product based on public health imperatives, and not on World Bank country classifications or geographical location; and that the licenses are for LEN for both prevention and treatment.

If approved, LEN for PrEP will add a potent new option to the prevention toolkit— alongside oral PrEP, injectable CAB and the dapivirine vaginal ring. But realizing the potential of highly protective interventions depends on accelerating and expanding access to the full suite of HIV prevention choices, and rolling out LEN better and faster than the options that came before. It has taken more than ten years to reach scale following the trial results that showed the life-saving benefits of F/TDF. The time from efficacy results to approval improved marginally with CAB for PrEP, while DVR moves slowly forward in expanding access. The field must not again squander months and years.



What can advocates do now?

- Talk to your community.** What might the results mean for them? Understanding specific questions and concerns will help frame advocacy priorities. Help communities understand the PURPOSE trials, the potential significance of LEN as an every six-month injection, the regulatory process and timelines, and the importance of scaling up existing PrEP programs in the meantime, with a range of choices.
- Demand equitable PrEP access and programming for choice.** This entails funding commitments, setting targets and embracing innovation. The global health community must July 2024 5 The Lens on LEN: The basics on injectable lenacapavir as PrEP move with speed, scale and urgency in designing, funding and implementing comprehensive and integrated PrEP programs that offer a choice of product and service delivery models.

- **Advocate for affordable pricing.** Gilead has not yet set a price for LEN for PrEP. Various cost-effectiveness analyses have shown that injectable PrEP must be priced in the range of generic daily oral TDF/FTC to be considered cost-effective. Modeling studies suggest that the generic price of LEN for PrEP could be as low as \$100 per person year of protection but only when the number of vials produced is equivalent to those needed for one million LEN users. This represents a significant increase in the current PrEP market and would require significant additional investment in product procurement and programming. While this may not be possible at product launch, the field needs to collaborate to reach this price point as quickly as possible and then, ideally, move to the price of daily oral PrEP. To reach these price points, it is essential to build volume in the market with supplies from Gilead at a price no higher than CAB for PrEP and to support multiple generic manufacturers to prepare for production at scale. Advocates must demand pricing transparency and a clear, accelerated pathway to cost-effective PrEP programs for everyone, everywhere, based on public health imperatives, and not on World Bank country classifications or geographical location.
- **Hold all decision-makers on LEN accountable.** Is there clarity about next steps? Are there targets and milestones in place? Is there adequate funding and available product to support rollout? How might decisions be made about who would get the product first, if it's licensed and introduced through phased rollout?
- **Work locally with research sites and PrEP programs.** Bring your advocacy know-how to sites for planned and ongoing research to ensure communication, access and continued work meet your needs.

Resources

- [Lenacapavir: The Case for investing in delivering HIV prevention](#), PXPulse podcast episode
- [The long wait for long-acting HIV prevention and treatment formulations](#), Lancet
- [A game-changer for PrEP if access is adequate](#), Lancet
- [Country-planning matrix to track introduction of next-generation PrEP](#), AVAC
- [The pipeline of products moving towards the market](#), AVAC infographic
- [Getting Rollout Right: Lessons from Oral PrEP](#), AVAC issue briefs
- [Coalition to Accelerate Access to Long-Acting PrEP](#), Coalition resources
- [BioPIC Adaptable Product Introduction Framework](#), BioPIC framework for rollout

About AVAC

AVAC is an international non-profit organization that leverages its independent voice and global partnerships to accelerate ethical development and equitable delivery of effective HIV prevention options, as part of a comprehensive and integrated pathway to global health equity. Follow AVAC on Twitter [@HIVpxresearch](#) and find more at www.avac.org.